PATTERN OF USING DRUGS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS IN THE VOLGOGRAD REGION

Download full text PDF
DOI: https://doi.org/None
Issue: 
2
Year: 
2015

Professor I.N. Tyurenkov, MD; E.G. Galtsova Volgograd State Medical University; 1, Pavshikh Bortsov Sq., Volgograd 400131

The authors analyzed the market of drugs for osteoporosis prevention and treatment in the Volgograd market and studied trends in the use of these medications in 2010-2012. The Volgograd market was represented by the following pharmacological groups: bisphosphonates, strontium ranelate, salmon calcitonin, denosumab, calcium and vitamin D supplements, and active vitamin D metabolites. The top 10 drugs for the treatment of osteoporosis in the Volgograd Region include Aclasta, Boniva, Ostalon, Osterepar, Risendros, Tevanat, Tevabon, Forosa (bisphosphonates), Bivalos (strontium ranelate), and Miacalcic (salmon calcitonin). All the top 10 drugs are manufactured in foreign countries. Powders and tablets make up the bulk of sold drugs in packages. The market leaders were Tevabon in 2010 and Bivalos in 2011 and 2012. The use of osteoporotic drugs steadily increases every year. Their intake rose by 1.8-fold in 2011 and by 1.5-fold in 2012 compared to 2010. Calcium supplements, such as Calcium-D3 Nycomed, Complevit Ca, and Calcemin, constitute the highest proportion among the preventive agents. Consumption prediction is made for the years immediately ahead.
Keywords: 
osteoporosis
alendronic acid
ibandronic acid
bisphosphonates
strontium ranelate
bone mineral density
References: 
  1. Lesnyak O.M. Audit sostoyaniya problemy osteoporoza v stranah vostochnoy Evropy i central`noy Azii 2010. Osteoporoz i osteopatii. 2011; 2: 3–6. [Lesnyak O.M. The status of the problem of osteoporosis in Eastern Europe and Central Asia, 2010. Osteoporos and osteopatii.2011; 2: 3–6 (in Russian)].
  2. Lesnyak O.M., Benevolenskaya L.I. Osteoporoz v Rossiyskoy Federacii: problemy i perspektivy. Nauchno-prakticheskaya revmatologiya. 2010; 5: 14–18 [Lesnyak O. M., Benevolenskaya L. I. Osteoporosis in the Russian Federation: Problems and Prospects. Nauchno – prakticheskayarevmatologiya.2010; 5: 14-18 (in Russian)].
  3. Osteoporoz (pod red. O. M. Lesnyak, L. I. Benevolenskoy). 2-e izd., pererab. i dop. M.: GE`OTAR–Mediya. 2010: 272 [Osteoporosis/ Editors: O.M. Lesnyak, L.I. Benevolenskaya.-2nd ed., rev. and add. M.: GEOTAR – Mediya. 2010, 272 )in Russian)].
  4. Mihaylov E.E., Benevolenskaya L.I., Barkova T.V. E`pidemiologicheskaya harakteristika perelomov kostey konechnostey v populyacionnoy vyborke lic 50 let i starshe. Osteoporoz i osteopatii. 1998; 2: 2–6 [Mikhailov E.E., Benevolenskaya L. I., Barkova T. C. Epidemiological characteristic of fractures of the extremities in a population-based sample of patients aged 50 and older. Osteoporos and osteopatii.1998; 2: 2-6 (in Russian)].
  5. Men`shikova L.V., Hramcova N.A., Ershova O.B. i dr. Blizhayshie i otdalennye ishody perelomov proksimal`nogo otdela bedra u lic pozhilogo vozrasta i ih mediko-social`nye posledstviya (po dannym mnogocentrovogo issledovaniya). Osteoporoziosteopatii. 2002; 1: 8–11 [Menshikova L.V., Khramtsova N.A., Ershova O.B., et al. Short-tern and long-term outcomes of fractures of the proximal femur in elderly patients and their medical and social effects (based on a multicenter study). Osteoporos and osteopatii.2002; 1: 8–11 (in Russian)].
  6. Ershova O.B., Belova K.Yu., Nazarova A.V. i dr. Rasprostranennost` perelomov proksimal`nogo otdela bedra sredi zhiteley Yaroslavlya. Osteoporoz i osteopatii. 2010: Tez. IV Ros. kongressa po osteoporozu (Sankt-Peterburg, 26–29 sentyabrya 2010 g.). SPb., 2010; Pril. 1: 33 [Ershova, O.B., Belova K.Y., Nazarova A.B. et al. The Incidence of fractures of the proximal femur among peopleliving in Yaroslavl.Osteoporos and osteopatii. 2010: Proceedingsof the IV Russian Osteoporosis Congress. (St. Petersburg, 26–29 September, 2010). SPb., 2010; Apps. 1: 33 (in Russian)].
  7. Shverc G.Ya. Tevabon – novyy kombinirovannyy preparat dlya lecheniya osteoporoza. RMZh. 2011; 5: 523-531 [Shverts G.Ya. Tevabon-a novel combined drug for the treatment of osteoporosis. RMJ. 2011; 5: 523-531 (in Russian)].
  8. Black D.M., Schwartz A.V., Ensrud K.E. et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA, 2006, Dec 27: 296 (24): 2927–2938.
  9. Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis // J. Bone Miner. Res., 2004: 19(8): 1241–1249